Agilon Health price target raised to $3 from $2 at Stifel

Stifel raised the firm’s price target on Agilon Health (AGL) to $3 from $2 and keeps a Hold rating on the shares. Part D exposure is reduced to 30% of the population in 2025, which helps reduce risk in areas Agilon has little to no control over, the analyst tells investors in a post-earnings note.